

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:
  - (a) providing a MUC1 test agent;
  - (b) providing a tumor progressor test agent that binds to the MUC1 test agent;
  - (c) contacting the MUC1 test agent with the tumor progressor test agent in the presence of a test compound, wherein the test compound is a compound that binds to MUC1; and
  - (d) determining whether the test compound inhibits binding of the MUC1 test agent to the tumor progressor test agent,  
wherein a test compound that inhibits binding of the MUC1 test agent to a tumor progressor test agent is a compound that inhibits binding of MUC1 to a tumor progressor.
2. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a c-Src test agent.
3. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a p120<sup>ctn</sup> test agent.
4. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

5. (Original) The method of claim 1, wherein the tumor progressor test agent is a  $\beta$ -catenin test agent.

6. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a protein kinase C $\delta$  (PKC $\delta$ ) test agent.

7. (Original) The method of claim 1, wherein the contacting is carried out in a cell-free system.

8. (Original) The method of claim 1, wherein the contacting occurs in a cell.

9. (New) A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:

(a) providing a MUC1 test agent;  
(b) providing a tumor progressor test agent that binds to the MUC1 test agent;  
(c) contacting the MUC1 test agent with the tumor progressor test agent in the presence of a test compound, wherein the test compound is a peptide fragment of the tumor progressor;  
and

(d) determining whether the test compound inhibits binding of the MUC1 test agent to the tumor progressor test agent,

wherein a test compound that inhibits binding of the MUC1 test agent to a tumor progressor test agent is a compound that inhibits binding of MUC1 to a tumor progressor.

10. (New) The method of claim 9, wherein the tumor progressor test agent is a c-Src test agent.

11. (New) The method of claim 9, wherein the tumor progressor test agent is a p120<sup>cas</sup> test agent.

12. (New) The method of claim 9, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

13. (New) The method of claim 9, wherein the tumor progressor test agent is a  $\beta$ -catenin test agent.

14. (New) The method of claim 9, wherein the tumor progressor test agent is a protein kinase C $\delta$  (PKC $\delta$ ) test agent.

15. (New) The method of claim 9, wherein the contacting is carried out in a cell-free system.

16. (New) The method of claim 1, wherein the contacting occurs in a cell.